Copyright
©2013 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Dec 21, 2013; 19(47): 8867-8872
Published online Dec 21, 2013. doi: 10.3748/wjg.v19.i47.8867
Published online Dec 21, 2013. doi: 10.3748/wjg.v19.i47.8867
Risk prediction of hepatitis B virus-related hepatocellular carcinoma in the era of antiviral therapy
Il Han Song, Young Kwang Choo, Division of Hepatology, Department of Internal Medicine, Dankook University College of Medicine, Cheonan 330-715, South Korea
So Mi Kim, Department of Internal Medicine, Jeju National University School of Medicine, Jeju 690-767, South Korea
Author contributions: Song IH performed the reference literature search and wrote this manuscript; Kim SM and Choo YK provided critical expertise with focusing this topic.
Correspondence to: Il Han Song, MD, PhD, Division of Hepatology, Department of Internal Medicine, Dankook University College of Medicine, 16-5 Anseo-dong, Cheonan 330-715, South Korea. ihsong21@dankook.ac.kr
Telephone: +82-41-5503924 Fax: +82-41-5563256
Received: August 28, 2013
Revised: October 23, 2013
Accepted: November 2, 2013
Published online: December 21, 2013
Processing time: 145 Days and 2.2 Hours
Revised: October 23, 2013
Accepted: November 2, 2013
Published online: December 21, 2013
Processing time: 145 Days and 2.2 Hours
Core Tip
Core tip: This review shows the concepts and perspectives of the risk prediction of hepatitis B virus-related hepatocellular carcinoma. Accurate risk scoring systems to predict hepatocellular carcinoma (HCC) development, derived from independent risk factors integrated in aspects of host, environment, and virus, are necessary for performing the strategic processes such as screening/surveillance, diagnosis, and treatment in high-risk individuals of HCC. Globally standardized consensus for HCC risk prediction models should be established on the basis of simplicity, assessability, and reproducibility of the model characteristics available in real clinical setting.